A medication called omalizumab (often sold as Xolair) has been around for a long time and was used to help deal with asthma.

The Johns Hopkins-led OUtMATCH study, which enrolled clinical trial participants at 10 locations across the U.S., leads to ...

Joseph spent his childhood dreading family gatherings. His Egyptian-American relatives would gather around the family table ...

The standard regimen of omalizumab is often modified in patients with chronic spontaneous urticaria, with several factors predicting dose adjustments.

The FDA has approved omalizumab to treat a type of hives called chronic spontaneous urticaria. It's approved to treat people 12 years of age and older who continue to get hives after taking ...

Clear Street initiated coverage of Rapt Therapeutics with a Buy rating and set a $3 price target, as the research firm has “strong conviction” in RPT904b as the company's candidate for the treatment ...

Extremely rarely, prolonged use on large areas can lead to more serious side effects from absorption into your bloodstream: Omalizumab is a treatment option for people who develop chronic hives ...

Patients with chronic spontaneous urticaria who are refractory to antihistamines who received rilzabrutinib had rapid response to treatment with no new safety signals identified. Rilzabrutinib may be ...